X4 Pharmaceuticals, Inc. Stock
Price
Target price
€1.09
€1.09
7.630%
0.08
7.630%
€2.76
26.04.24 / Tradegate
WKN: A2PFVY / Symbol: XFOR / Name: X4 Pharmaceuticals / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
X4 Pharmaceuticals, Inc. Stock
X4 Pharmaceuticals, Inc. dominated the market today, gaining €0.080 (7.630%).
Currently there is a rather positive sentiment for X4 Pharmaceuticals, Inc. with 5 Buy predictions and 0 Sell predictions.
With a target price of 2 € there is a hugely positive potential of 83.65% for X4 Pharmaceuticals, Inc. compared to the current price of 1.09 €.
So far the community has only identified positive things for X4 Pharmaceuticals, Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of X4 Pharmaceuticals, Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
B****
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of X4 Pharmaceuticals, Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| X4 Pharmaceuticals, Inc. | 7.630% | -7.555% | -19.333% | -19.926% | 39.615% | - | - |
| Ardelyx Inc. | 3.600% | -1.640% | -12.849% | 41.749% | 3.737% | -16.140% | - |
| Salarius Pharmaceuticals Inc. | 1.400% | 3.333% | 6.373% | -63.833% | -21.802% | -98.281% | -99.993% |
| Brainstorm Cell | -5.760% | -2.456% | -18.607% | -82.011% | 114.009% | -83.339% | - |
Comments
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Show more
Ratings data for XFOR provided by MarketBeat
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "buy" rating re-affirmed by analysts at B. Riley.
Show more
Ratings data for XFOR provided by MarketBeat
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Show more
Ratings data for XFOR provided by MarketBeat